-
Mashup Score: 02022 ASCO Gastrointestinal Cancers Symposium Highlights - 2 year(s) ago
Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HIMALAYA: tremelimumab + durvalumab in unresectable HCC - 2 year(s) ago
Richard D. Kim, MD, Moffitt Cancer Center, Tampa, FL, discusses the results of HIMALAYA, (NCT03298451), an open-label, randomized, multicenter, Phase…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Richard Kim of @MoffittNews talks on the HIMALAYA trial: tremelimumab + durvalumab in unresectable HCC Watch: 👉https://t.co/7qIrhhPkhf👈 @ASCO #GI22 #CRCSM #PancSM #ESOCsm #STCsm #HPBCsm
-
-
Mashup Score: 0A Phase I/II investigating the addition of IO to the standard of care for patients with MSS mCRC - 2 year(s) ago
Van K. Morris, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the Phase I/II trial evaluating…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Van Morris of @MDAndersonNews discusses the Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. Watch: 👉https://t.co/WTDcnzSxFv👈 @ASCO #GI22 #CRCSM #PancSM #ESOCsm #STCsm #HPBCsm
-
-
Mashup Score: 0Oncology Nursing News - 2 year(s) ago
homejournalsoncology-nurseOncology Nursing News® is published 6 print issues every year. This page features the content from those publications.April 2022Volume: 16Issue: 2February 2022Volume: 16Issue: 1December 2021Volume: 15Issue: 6October 2021Volume: 15Issue: 5August 2021Volume: 15Issue: 4June 2021Volume: 15Issue: 3April 2021Volume: 15Issue: 02February 2021Volume: 15Issue: 1February…
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Our April 2022 Issue is here! Download and read now: https://t.co/Xf57eqdERH #oncologynurse #oncology #diversity #DEI #decentralizedtrials #clinicaltrials #childhoodcancer #DNP #advancedpracticeproviders #GU22 #GI22 #oncologynursing https://t.co/U3wuGHGNG3
-
-
Mashup Score: 0
Rana R. McKay, MD, discusses findings from a real-world study on genomic alterations of metastases in renal cell carcinoma, the rationale of the phase 3 COSMIC-313 trial in patients with previously untreated advanced or metastatic RCC, plus findings from the phase 1/2 COMRADE trial in patients with metastatic castration-resistant prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@DrRanaMcKay, of @UCSDHealth, discusses genomic alterations of metastases in RCC, the rationale of the phase 3 COSMIC-313 trial in patients with previously untreated advanced or metastatic RCC, plus findings from the phase 1/2 COMRADE trial #GI22 #kcsm https://t.co/PofZ6x2Vpg
-
-
Mashup Score: 0BI 836880/Ezabenlimab Combo Had Limited Antitumor Activity, But Manageable Safety in Advanced MSS CRC - 2 year(s) ago
The VEGF/Ang2–targeting bispecific nanobody BI 836880, in combination with ezabenlimab, produced antitumor activity found to be comparable to that of available third-line therapy options in patients with advanced microsatellite stable colorectal cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to data from a subset of patients within module C of a phase 2 trial BI 836880 in combo w/ ezabenlimab produced antitumor activity comparable to that of available third-line therapy options in advanced microsatellite stable CRC. #GI22 #crcsm https://t.co/1Si3TXkSdb https://t.co/OJexgtughJ
-
-
Mashup Score: 0BI 836880/Ezabenlimab Combo Had Limited Antitumor Activity, But Manageable Safety in Advanced MSS CRC - 2 year(s) ago
The VEGF/Ang2–targeting bispecific nanobody BI 836880, in combination with ezabenlimab, produced antitumor activity found to be comparable to that of available third-line therapy options in patients with advanced microsatellite stable colorectal cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The VEGF/Ang2–targeting bispecific nanobody BI 836880, in combination with ezabenlimab, produced antitumor activity found to be comparable to that of available third-line therapy options in patients with advanced microsatellite stable CRC. #GI22 #crcsm https://t.co/2JmNnKf6E1
-
-
Mashup Score: 0Bavdegalutamide Showcases Early Activity in Metastatic Castration-Resistant Prostate Cancer - 2 year(s) ago
The novel androgen receptor PROTAC degrader, bavdegalutamide, was found to be clinically active and tolerable with manageable adverse effects in patients with metastatic castration-resistant prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The novel androgen receptor PROTAC degrader, bavdegalutamide, was found to be clinically active and tolerable with manageable adverse effects in patients with metastatic castration-resistant prostate cancer. @MassGeneralNews #GI22 #pcsm https://t.co/dMJ9wNVBr9
-
-
Mashup Score: 2Adjuvant Therapy for Colon Cancer Impact of Stopping Treatment Early - The ASCO Post - 2 year(s) ago
For patients with stage III colon cancer, early discontinuation of adjuvant chemotherapy leads to worse outcomes—but early discontinuation of oxaliplatin did not. These findings, which came from an analysis of the large ACCENT and IDEA clinical trials databases, were presented at the 2022 ASCO Gastrointestinal Cancers…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adjuvant Therapy for Colon Cancer: Impact of Stopping Treatment Early https://t.co/MT2EideiWn #GI22 #oncology #cancer #crcsm
-
-
Mashup Score: 0Bavdegalutamide Showcases Early Activity in Metastatic Castration-Resistant Prostate Cancer - 2 year(s) ago
The novel androgen receptor PROTAC degrader, bavdegalutamide, was found to be clinically active and tolerable with manageable adverse effects in patients with metastatic castration-resistant prostate cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to data from the phase 1/2 ARDENT trial, bavdegalutamide was found to be clinically active and tolerable with manageable adverse effects in patients with metastatic castration-resistant prostate cancer. @MassGeneralNews #GI22 #pcsm https://t.co/xO0xbNdIdZ https://t.co/N1pVnYiu9W
-
ICYMI: 2022 ASCO gastrointestinal cancers symposium highlights #GI22 #oncology #oncologynurse https://t.co/UbO7wmR9ve